Don’t believe these money misconceptions: 3 things to know that can help improve your finances
Many people believe common misconceptions about managing their money. Here’s what you need to know to improve your personal finances.
Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune.
Venice residents clash with riot police as city launches world’s first tourist entry fee
The pilot program means day-trippers to Venice, one of Italy’s most picturesque and historic cities, will need to pay a charge of 5 euros (US$5.40).
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
The first-quarter results come as Merck shows substantial progress in preparing for Keytruda’s patent expiration in 2028.
Amazon aggregator Thrasio loses CEO, other top execs as company works through bankruptcy
Thrasio, an early leader in the Amazon aggregator space, is undergoing an overhaul of its C-Suite two months after the company entered bankruptcy.
Mark Meadows, Rudy Giuliani and Arizona ‘fake electors’ charged with state crimes
State Attorney General Kris Mayes announced the indictments of Trump aides and allies after an investigation into efforts to overturn the 2020 election.
GDP report Thursday expected to show economy still growing at a solid pace
The sum of all goods and services is expected to post 2.4% annualized growth for the three months ended in March.
Rep. Donald Payne Jr. dies at age 65
With Payne’s death and the recent resignation of Rep. Mike Gallagher, R-Wis., from the House, the margin in the lower chamber now is 217 Republicans to 212 Democrats.
Ford tops first-quarter earnings estimates as commercial unit offsets EV losses
Sales of Ford Motor trucks and other commercial vehicles led the automaker to beat Wall Street’s earnings estimates for the first quarter.
Wells Fargo becomes bullish on this biotech company
Wells Fargo believes the company’s hyperplasia and depression treatments could each become over $1 billion opportunities.
